Ilana Graetz1, Caitlin N McKillop2, Edward Stepanski3,4, Gregory A Vidal3,5, Janeane N Anderson3, Lee S Schwartzberg3,4,5. 1. Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, 66 N. Pauline St., Ste. 633, Memphis, TN, 38163, USA. igraetz@uthsc.edu. 2. Department of Economics, State University of New York at Cortland, 28 Graham Ave., Cortland, NY, 13045, USA. 3. Department of Preventive Medicine, College of Medicine, University of Tennessee Health Science Center, 66 N. Pauline St., Ste. 633, Memphis, TN, 38163, USA. 4. Vector Oncology, 6555 Quince Rd #400, Memphis, TN, 38119, USA. 5. West Cancer Center, 7945 Wolf River Blvd, Germantown, TN, 38138, USA.
Abstract
PURPOSE: For postmenopausal women with hormone receptor-positive breast cancer, long-term use of aromatase inhibitors (AIs) significantly reduces the risk of cancer recurrence and improves survival. Still, many patients are nonadherent due to adverse side effects. We conducted a pilot randomized controlled trial to test the use of a web-based application (app) designed with and without weekly reminders for patients to report real-time symptoms and AI use outside of clinic visits with built-in alerts to patients' oncology providers. Our goal was to improve symptom burden and medication adherence. METHODS:Forty-four women with early-stage breast cancer and a new AI prescription were randomized to either an App+Reminder (weekly reminders to use app) or an App (no reminders) group. Pre- and post-assessment data were collected from all participants. RESULTS: Participants in the App+Reminder group had higher weekly app usage rate (74 vs. 38%, p < 0.05) during the intervention and reported higher AI adherence at 8 weeks (100 vs. 72%, p < 0.05). Symptom burden increase was higher for the App group compared to the App+Reminder group but did not reach statistical significance. CONCLUSIONS: Weekly reminders to use a web-based app to report AI adherence and treatment-related symptoms demonstrated feasibility and improved short-term AI adherence, which may reduce symptom burden for women with breast cancer and a new AI prescription. IMPLICATIONS FOR CANCER SURVIVORS: If short-term gains in adherence persist, this low-cost intervention could improve survival outcomes for women with breast cancer. A larger, long-term study should examine if AI adherence and symptom burden improvements persist for a 5-year treatment period.
RCT Entities:
PURPOSE: For postmenopausal women with hormone receptor-positive breast cancer, long-term use of aromatase inhibitors (AIs) significantly reduces the risk of cancer recurrence and improves survival. Still, many patients are nonadherent due to adverse side effects. We conducted a pilot randomized controlled trial to test the use of a web-based application (app) designed with and without weekly reminders for patients to report real-time symptoms and AI use outside of clinic visits with built-in alerts to patients' oncology providers. Our goal was to improve symptom burden and medication adherence. METHODS: Forty-four women with early-stage breast cancer and a new AI prescription were randomized to either an App+Reminder (weekly reminders to use app) or an App (no reminders) group. Pre- and post-assessment data were collected from all participants. RESULTS:Participants in the App+Reminder group had higher weekly app usage rate (74 vs. 38%, p < 0.05) during the intervention and reported higher AI adherence at 8 weeks (100 vs. 72%, p < 0.05). Symptom burden increase was higher for the App group compared to the App+Reminder group but did not reach statistical significance. CONCLUSIONS: Weekly reminders to use a web-based app to report AI adherence and treatment-related symptoms demonstrated feasibility and improved short-term AI adherence, which may reduce symptom burden for women with breast cancer and a new AI prescription. IMPLICATIONS FOR CANCER SURVIVORS: If short-term gains in adherence persist, this low-cost intervention could improve survival outcomes for women with breast cancer. A larger, long-term study should examine if AI adherence and symptom burden improvements persist for a 5-year treatment period.
Authors: Jessica M Franklin; Alexis A Krumme; William H Shrank; Olga S Matlin; Troyen A Brennan; Niteesh K Choudhry Journal: Am J Manag Care Date: 2015-09-01 Impact factor: 2.229
Authors: Carol E DeSantis; Stacey A Fedewa; Ann Goding Sauer; Joan L Kramer; Robert A Smith; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-10-29 Impact factor: 508.702
Authors: Dawn L Hershman; Jennifer Tsui; Jason D Wright; Ellie J Coromilas; Wei Yann Tsai; Alfred I Neugut Journal: J Clin Oncol Date: 2015-02-17 Impact factor: 44.544
Authors: Shruti Bhandari; Phuong Ngo; Blakely Kute; Mounika Mandadi; Whitney A Pitman; Xiaoyong Wu; Sandy Lloyd; Marie Corliss Brown; Shesh N Rai; Dharamvir Jain; Elizabeth C Riley Journal: Breast Cancer Res Treat Date: 2019-06-06 Impact factor: 4.872
Authors: Shoshana M Rosenberg; Keith J Petrie; Annette L Stanton; Lan Ngo; Emma Finnerty; Ann H Partridge Journal: J Natl Cancer Inst Date: 2020-05-01 Impact factor: 13.506
Authors: Janeane N Anderson; J Carolyn Graff; Rebecca A Krukowski; Lee Schwartzberg; Gregory A Vidal; Teresa M Waters; Andrew J Paladino; Tameka N Jones; Ryan Blue; Mehmet Kocak; Ilana Graetz Journal: Health Commun Date: 2020-04-26
Authors: Eng Hooi Tan; Andrea Li Ann Wong; Chuan Chien Tan; Patrick Wong; Sing Huang Tan; Li En Yvonne Ang; Siew Eng Lim; Wan Qin Chong; Jingshan Ho; Soo Chin Lee; Bee Choo Tai Journal: Breast Date: 2020-07-02 Impact factor: 4.380
Authors: Zoe Moon; Mira Zuchowski; Rona Moss-Morris; Myra S Hunter; Sam Norton; Lyndsay D Hughes Journal: Support Care Cancer Date: 2021-07-08 Impact factor: 3.603
Authors: Janeane N Anderson; Rebecca A Krukowski; Andrew J Paladino; J Carolyn Graff; Lee Schwartzberg; Andrea N Curry; Gregory A Vidal; Tameka N Jones; Teresa M Waters; Ilana Graetz Journal: J Hosp Manag Health Policy Date: 2021-03-25